Nonosseous abnormalities on bone scans

Journal of Nuclear Medicine Technology

Volumn 31, Issue 3, 2003, Pages 149-156

  Loutfi, Issa ^a   Collier, B David ^b   Mohammed, Ahmed M ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b NONE

Author keywords

Bone scintigraphy; Breast cancer; Malignant pleural effusion; Renal cell carcinoma

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; MEDRONIC ACID; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TECHNETIUM PHOSPHATE TC 99M; DIAGNOSTIC AGENT;

ARTICLE; ARTIFACT; BONE SCINTISCANNING; BREAST CANCER; HETEROTOPIC OSSIFICATION; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; KIDNEY CARCINOMA; PLEURA EFFUSION; RADIOACTIVITY; RADIODIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE TUMOR; BONE; CONNECTIVE TISSUE; CONTRAST MEDIUM EXTRAVASATION; DIFFERENTIAL DIAGNOSIS; INCIDENTAL FINDING; METABOLISM; METHODOLOGY; REVIEW; SCINTISCANNING; URINARY TRACT DISEASE; VISCERA;

ARTIFACTS; BONE AND BONES; CONNECTIVE TISSUE; DIAGNOSIS, DIFFERENTIAL; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; INCIDENTAL FINDINGS; SOFT TISSUE NEOPLASMS; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UROLOGIC DISEASES; VISCERA;

EID: 1542442575     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. O'Connor MK, Brown ML, Hung JC, Hayostek RJ. The art of bone scintigraphy: technical aspects. J Nucl Med. 1991;32:2332-2341.
2. Citrin DL. Problems and limitations of bone scanning with Tc-99m phosphates. Clin Radiol. 1977;28:97-105.
3. McAfee JC, Singh A, Roskopf M, et al. Experimental drug-induced changes in renal function and biodistribution of Tc-99m MDP. Invest Radiol. 1983;18:470-478.
4. Hung JC, Ponto JA, Hammes RJ. Radiopharmaceutical-related pitfalls and artifacts. Semin Nucl Med. 1996;26:208-255.
5. Wilson MA, Pollack MJ. Gastric visualization and image quality in radionuclide bone scanning: concise communication. J Nucl Med. 1981;22:518-521.
6. Chaudhuri TK. The effect of aluminum and pH on altered body distribution of Tc-99m EHDP. Int J Nucl Med Biol. 1976;3:37.
7. Al-Enizi E, Kazem N, Owunwanne A, Collier BD, Mathews M. Dextrose solutions yield radiopharmaceutical impurities: the "sweet" scans. J Nucl Med Technol. 2003;31:33-36.
8. Billinghurst MW, Rempel S, Westendorf BA. Radiation decomposition of technetium-99m radiopharmaceuticals. J Nucl Med. 1979;20:138-143.
9. Sherkow L, Ryo UY, Fabich D, Patel GC, Pinsky SM. Visualization of the liver, gallbladder and intestine on bone scintigraphy. Clin Nucl Med. 1984;9:440-443.
10. Krasnow AZ, Collier BD, Isitman AT, Hellman RS, Ewey D. False-negative bone imaging due to etidronate disodium therapy. Clin Nucl Med. 1988;13:264-267.
11. Choy D, Murray IP, Hoschl R. The effect of iron on the biodistribution of bone scanning agents in humans. Radiology. 1981;140:197-202.
12. Lutrin CL, McDougall IR, Goris ML. Intense concentration of technetium-99m pyrophosphate in the kidneys of children treated with chemotherapeutic drugs for malignancy. Radiology. 1978;128:165-167.
13. Wallis JW, Fisher S, Wahl RL. Tc-99m MDP uptake by lymph nodes following tracer infiltration: clinical and laboratory evaluation. Nucl Med Commun. 1987;8:357-363.
14. Andrews GA, Theocheung JL, Andrews E, Tyler KR. Unintentional intra-arterial injection of a bone imaging agent. Clin Nucl Med. 1980;5:499-501.
15. Kessler JR, Wells RG, Sty JR. Skeletal scintigraphy: radiographic artifacts. Clin Nucl Med. 1992;17:511-512.
16. O'Connor MK, Kelly BJ. Evaluation of techniques for the elimination of "hot" bladder artifacts in SPECT of the pelvis. J Nucl Med. 1990;31:1872-1875.
17. Vieras F, Boyd CM. Diagnostic value of renal imaging incidental to bone scintigraphy with Tc-99m phosphate compounds. J Nucl Med. 1975;16:1109-1114.
18. Wulfeck DW, Sakow NK, Senler S. Detection of recurrent renal cell carcinorma by three-phase bone scan. Clin Nucl Med. 1993;18:441-443.
19. Biello DR, Coleman RE, Stanley RJ. Correlation of renal images on bone scan and intravenous pyelogram. AJR. 1976;127:633-636.
20. Kanmaz B, Collier BD, Liu Y, et al. SPET and three-phase planar bone scintigraphy in adult patients with chronic low back pain. Nucl Med Commun. 1988;19:13-21.
21. Rossier AB, Bussat P, Infante F, et al. Current facts of para-osteo-arthropathy (POA). Paraplegia. 1973;11:38-78.
22. Tanaka T, Rossier AB, Hussey RW, Ahnberg DS, Treves S. Quantitative assessment of para-osteo-arthropathy and its maturation on serial radionuclide bone images. Radiology. 1977;123:217-221.
23. Suzuki Y, Hisada K, Takeda M. Demonstration of myositis ossificans by Tc-99m pyrophosphate bone scanning. Radiology. 1974;111:663-664.
24. Silberstein EB, Francis MD, Tofe AJ, Slough CL. Distribution of Tc-99m-Sn diphosphonate and free Tc-99m pertechnetate in selected hard and soft tissues. J Nucl Med. 1975;16:58-61.
25. Janssen S, Piers DA, van Rijswijk MH, Meijer S, Mandema E. Soft-tissue uptake of Tc-99m-diphosphonate and Tc-99m-pyrophosphate in amyloidosis. Eur J Nucl Med. 1990;16:663-670.
26. Siegel ME, Walker WJ, Campbell JL. Accumulation of Tc-99m-diphosphonate in malignant pleural effusions: detection and verification. J Nucl Med. 1975;16:883-885.
27. Silberstein EB, Delong S, Cline J. Tc-99m diphosphonate and sulphur colloid uptake by the spleen in sickle disease: interrelationship and clinical correlates - concise communication. J Nucl Med. 1984;25:1300-1303.
28. Romyn AM, Bushnell DL, Freeman ML, Kaplan E. Visualization of metastatic liver disease on technetium-99m bone scintigraphy. Clin Nucl Med. 1987;12:264-267.
29. Buxton-Thomas MS, Wraight EP. High renal activity on bone scintigrams: a sign of hypercalcaemia? Br J Radiol. 1983;56:911-914.
30. Koizumi K, Tonami N, Hisada K. Diffusely increased Tc-99m-MDP uptake in both kidneys. Clin Nucl Med. 1981;6:362-365.
31. Lutrin CL, Goris ML. Pyrophosphate retention by previously irradiated renal tissue. Radiology. 1979;133:207-209.
32. Burnett KR, Lyons KP, Brown WT. Uptake of osteotropic radionuclides in the breast. Semin Nucl Med. 1984;14:48-49.